KORU Medical Systems (NASDAQ:KRMD) Announces Quarterly Earnings Results

KORU Medical Systems (NASDAQ:KRMD) released its quarterly earnings results on Wednesday. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03, Zacks reports. The business had revenue of $12.05 million for the quarter, compared to analyst estimates of $11.62 million. KORU Medical Systems had a negative net margin of 5.27% and a negative return on equity of 13.61%.

Here are the key takeaways from KORU Medical Systems’ conference call:

• Q2 revenue reached a record $12 million, up 18% year over year, driven by 12% growth in domestic core revenue and 59% international growth. Management said domestic demand, patient retention, new starts, and market-share gains remain strong.
• Gross margin improved to 65.1% from 63.5% a year ago, supported by manufacturing efficiencies, pricing, mix, and improved supplier terms. KORU also reported positive net income for the first time since 2019, positive operating cash flow in the quarter, and reiterated expectations for positive adjusted EBITDA for the full year.
• The company narrowed 2026 revenue guidance to $47.5 million-$48.5 million from its prior outlook, citing slower-than-expected launches in certain international, non-tender markets. Management now expects some of that prefilled-syringe opportunity to contribute more meaningfully in 2027.
• KORU withdrew its U.S. PHESGO 510(k) application after discussions with the FDA and will pursue other oncology biologics instead, delaying its planned U.S. oncology entry. PHESGO remains part of the international strategy, but additional real-world evidence and regulatory work are required.
• The company acquired connected-monitoring technology intended to add adherence tracking, real-world evidence, and patient support to its infusion platform, though management characterized it as a multi-year development effort. KORU also said Freedom 360 development has cleared its highest-risk stages and remains on track for a U.S. 510(k) submission by the end of 2027.

KORU Medical Systems Stock Performance

KORU Medical Systems stock traded down $0.57 during midday trading on Thursday, hitting $3.56. 1,074,221 shares of the company were exchanged, compared to its average volume of 166,686. The business has a fifty day simple moving average of $4.13 and a two-hundred day simple moving average of $4.39. The firm has a market capitalization of $163.52 million, a PE ratio of -71.20 and a beta of 0.45. KORU Medical Systems has a fifty-two week low of $3.21 and a fifty-two week high of $6.61.

Insider Buying and Selling

In related news, insider Adam R. Kalbermatten acquired 12,500 shares of the stock in a transaction on Thursday, June 11th. The shares were acquired at an average price of $3.94 per share, for a total transaction of $49,250.00. Following the transaction, the insider owned 312,500 shares in the company, valued at approximately $1,231,250. This trade represents a 4.17% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders purchased 28,000 shares of company stock valued at $109,430. Corporate insiders own 18.50% of the company’s stock.

Institutional Trading of KORU Medical Systems

Hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its position in shares of KORU Medical Systems by 52.1% in the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock valued at $39,000 after buying an additional 3,478 shares in the last quarter. Barclays PLC grew its stake in KORU Medical Systems by 8.8% in the 4th quarter. Barclays PLC now owns 67,442 shares of the company’s stock valued at $392,000 after acquiring an additional 5,457 shares during the period. Invesco Ltd. grew its stake in KORU Medical Systems by 24.8% in the 4th quarter. Invesco Ltd. now owns 27,873 shares of the company’s stock valued at $162,000 after acquiring an additional 5,546 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in KORU Medical Systems by 26.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,036 shares of the company’s stock worth $158,000 after acquiring an additional 5,649 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of KORU Medical Systems by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,022,860 shares of the company’s stock valued at $5,944,000 after purchasing an additional 16,062 shares during the period. 58.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

KRMD has been the topic of several research analyst reports. Weiss Ratings upgraded KORU Medical Systems from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 30th. Craig Hallum restated a “buy” rating and set a $6.00 price target on shares of KORU Medical Systems in a research note on Thursday. Finally, Wall Street Zen upgraded shares of KORU Medical Systems from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, KORU Medical Systems has a consensus rating of “Moderate Buy” and an average target price of $7.00.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.